Bloodwork

Question 1

How long does it take for testosterone levels to recover after a cycle?

Accepted Answer

Recovery timeline is a distribution, not a deadline. The median user on a standard first cycle recovers to 80% of baseline total testosterone at week 8–10 post-PCT. The tail extends further — 5–10% of users at week 12, a smaller fraction beyond 16 weeks, and a residual population that never reaches pre-cycle baseline. Cycle duration, compound profile, prior suppression exposure, and on-cycle hCG status all shift the distribution. First cycle, SERM-based PCT 10–12 week cycle, ≤500 mg/week testosterone, 4-week SERM PCT: Week 4 post-PCT: Total T 300–500 ng/dL in most responders. LH and FSH rising and detectable. Week 6–8: Total T within 20% of pre-cycle baseline in roughly 70% of users. The decision panel point. Week 10–12: Near-complete serum recovery in the median user. Libido, mood, and energy lag 2–4 weeks behind the numbers — SHBG rebound and tissue-level androgen receptor resensitisation run on separate clocks. Second and later cycles&hellip;

Question 2

What bloodwork panel should I pull before starting a cycle?

Accepted Answer

Baseline labs are the denominator for every subsequent reading. A bloodwork without pre-cycle baseline is a number without a reference — you cannot detect drift in a value whose starting point is unknown. The 80–150 EUR cost of a private direct-to-consumer panel is the cheapest insurance line in protocol design. The full pre-cycle panel — by physiological system Hormones Total testosterone — baseline for all suppression and recovery comparisons. Free testosterone — measured by direct assay or calculated via Vermeulen equation from total T + SHBG + albumin. The biologically active fraction; the number that maps to symptoms. SHBG — mandatory alongside total and free T. Predicts compound response: low-SHBG users see amplified effects from stanozolol and oxandrolone; high-SHBG users need dose adjustments upward for equivalent clinical effect. Estradiol — sensitive LC-MS/MS assay specifically. Standard immunoassay (ECLIA, ELISA) overestimates low values and underestimates high values in the male reference range.&hellip;

Question 3

Which estradiol assay should I use — sensitive or regular?

Accepted Answer

Sensitive (LC-MS/MS), without exception, for any male population. Standard immunoassay was developed for measuring elevated estradiol in pre-menopausal female reproductive endocrinology — a context where serum estradiol runs 50–400 pg/mL across the menstrual cycle. The assay was never optimised for the 10–50 pg/mL range relevant to males. Using it on male blood produces measurement error large enough to drive clinically significant misdosing. Why immunoassay fails in the male reference range — the cross-reactivity mechanism Steroid hormones share the cyclopentanoperhydrophenanthrene nucleus — four fused rings, 17 carbons, structural variation only at side groups. The estradiol immunoassay uses an antibody raised against a specific estradiol epitope. That antibody binds estradiol with high affinity but also binds structurally similar steroids with measurable affinity: estrone, estriol, testosterone, DHEA-sulfate, and various conjugated metabolites all generate non-zero signal. In a pre-menopausal woman with serum estradiol of 200 pg/mL, the cross-reactive contribution from other steroids is a&hellip;

Question 4

My ALT and AST came back high — should I stop the cycle?

Accepted Answer

The decision matrix has three inputs: which compound class you are running (oral 17α-alkylated vs injectable), the ratio of AST to ALT and the CK reading (muscle vs liver source differential), and the absolute ALT value relative to upper reference limit. Each combination produces a different action. The raw "my ALT is 85" reading does not contain enough information to decide on its own. Source differential — the AST/ALT/CK triangulation ALT (alanine aminotransferase) is the more hepatocyte-specific enzyme. AST (aspartate aminotransferase) is expressed in hepatocytes but also in skeletal muscle, cardiac muscle, and erythrocytes. CK (creatine kinase) is muscle-specific. The pattern of these three discriminates muscle-origin elevation from hepatic-origin elevation: Muscle origin: AST elevated, ALT mildly elevated or normal, CK markedly elevated, AST/ALT ratio >1. Classic pattern after a heavy training session or rhabdo-lite. No liver pathology indicated. Hepatic origin (oral AAS): ALT elevated, AST elevated proportionally, CK normal or&hellip;

Question 5

What is a safe hematocrit level on testosterone?

Accepted Answer

Testosterone drives erythropoiesis through two converging pathways: direct renal erythropoietin stimulation and suppression of hepcidin, which releases iron from macrophage storage and increases bone-marrow iron availability. The resulting rise in red cell mass is the single most consistently tracked adverse biomarker in the TRT and AAS cardiovascular literature. The reference frame Adult male reference range: 40–52% hematocrit. Watch zone (TRT/cruise): 52–54%. No immediate action; tighten monitoring cadence. Action threshold: >54%. Phlebotomy indicated. Hard stop: >58%. Frank polycythaemia with documented stroke, MI, and DVT signal in the cardiovascular outcomes literature. Plasma viscosity at 58% is approximately double the value at 48%. Shear stress on endothelium scales with viscosity; coagulation cascade activation follows. The risk is not hypothetical — the bodybuilder cardiovascular mortality case series identify erythrocytosis as the single adverse biomarker most consistently present at presentation. Why it climbs Testosterone directly stimulates renal EPO release and concurrently suppresses hepcidin expression. Hepcidin&hellip;

Question 6

How often should I pull bloods on a cruise dose?

Accepted Answer

Cruise dose (typically 125–200 mg/week testosterone) is exogenous androgen replacement at supraphysiological-edge serum concentration. The body adapts to it, the markers stabilise, and the casual user concludes that monitoring frequency can drop. The cardiovascular outcomes literature does not support that conclusion. Cruise is multi-year integrated exposure; the relevant adverse signals (HCT drift, lipid degradation, prolactin elevation on 19-nor protocols) accumulate over months-to-years and are visible only on longitudinal trend, not on single-draw snapshots. Frequency framework — risk-stratified by stability First 6 months on cruise: every 8 weeks. The window during which the protocol is being titrated to the individual: dose adjustment, AI titration, baseline establishment for marker drift detection. Higher cadence allows responsive adjustment before drift becomes problematic. Stable cruise (established numbers, ≥6 months at fixed dose, no concerning drift): every 3 months. The maintenance cadence — sufficient to detect emerging drift in HCT, lipids, or prolactin before the marker&hellip;